Patients with Huntington's often receive anti-dopaminergic medications, such as neuroleptic medications or vesicular monoamine transporter type 2 (VMAT2) inhibitors, to manage chorea and some ...

The movement disorder is characterized by involuntary movements known as chorea, and by the impairment of voluntary movements. The latter often presents the greatest disability resulting in reduced ...

SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington's disease, improving the involuntary, jerky movements known as chorea that are a key symptom of ...

Ingrezza (valbenazine) is a prescription drug that’s used to treat tardive dyskinesia and chorea caused by Huntington’s disease. Ingrezza can cause mild to serious side effects. Examples ...